FIGURE 5 | Correlation between NRlncRNA signature and drug sensitivity. Box plots for the estimated IC 50 of drugs between high- and low-risk BRCA patients. Bleomycin (A) , Bortezomib (B) , Cisplatin (C) , Dasatinib (D) , Doxorubicin (E) , Ge fi tinib (F) , Lapatinib (G) , Paclitaxel (H)